Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.09.10
- Author:
Peng SONG
1
;
Li ZHANG
1
;
Congcong SHANG
1
Author Information
1. Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
ALK gene;
ALK-TKI;
Detection method;
Drug resistance;
NSCLC
- MeSH:
Anaplastic Lymphoma Kinase;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
enzymology;
genetics;
Drug Resistance, Neoplasm;
genetics;
Gene Fusion;
Humans;
Lung Neoplasms;
drug therapy;
enzymology;
genetics;
Protein Kinase Inhibitors;
pharmacology;
therapeutic use;
Receptor Protein-Tyrosine Kinases;
antagonists & inhibitors;
genetics
- From:
Chinese Journal of Lung Cancer
2018;21(9):703-711
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work.
.
